Dongsung Pharmaceutical KRX:002210KOSPI
동성제약 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days1
Articles tracked0since Sep 11
In Q2 2026, Dongsung Pharmaceutical reported revenue of ₩22.1bn, up 10.6% year on year, and an operating loss of ₩2.0bn. Dongsung Pharmaceutical (동성제약) appeared in 0 Korean news articles and 1 DART filing over the past seven days.
Filing signals Litigation Screener
Dongsung Pharmaceutical quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩22.1bn | +10.6% | −₩2.0bn | −₩5.9bn |
| Q1 2026 | ₩19.1bn | -27.4% | ₩289m | ₩14m |
| Q4 2025 derived | ₩19.1bn | -15.5% | −₩7.1bn | −₩5.8bn |
| Q3 2025 | ₩21.8bn | +1.7% | ₩411m | ₩112m |
| Q2 2025 | ₩20.0bn | -8.2% | −₩4.2bn | −₩18.8bn |
| Q1 2025 | ₩26.3bn | +16.0% | ₩743m | −₩1.3bn |
| Q4 2024 derived | ₩22.6bn | +3.8% | −₩3.1bn | −₩11.9bn |
| Q3 2024 | ₩21.4bn | -2.8% | −₩698m | −₩1.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases.
Dongsung Pharmaceutical top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.
Latest Dongsung Pharmaceutical news Korean headlines
No articles yet.